Prostate carcinoma
Item
male patients with histologically confirmed prostate cancer
boolean
C0600139 (UMLS CUI [1])
Castration Levels of Testosterone | Luteinizing Hormone-releasing Hormone Agonist | Orchiectomy
Item
patients must have castrate levels of testosterone (< 50 ng/dl) on lhrh analogue or have had prior orchiectomy.
boolean
C4289828 (UMLS CUI [1])
C1518041 (UMLS CUI [2])
C0029189 (UMLS CUI [3])
Neoplasm Metastasis Quantity Radiography | Cross-sectional imaging Chest | Cross-sectional imaging Abdomen | Cross-sectional imaging Pelvis | Whole body bone scan | Tumor Biopsy | Interventional radiology
Item
presence of one or more metastases by standard radiographic scans including cross-sectional imaging of the chest/abdomen/pelvis and whole body bone scan that is safely accessible to tumor biopsy in the judgment of treating clinician and/or interventional radiology
boolean
C0027627 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0034571 (UMLS CUI [1,3])
C3824793 (UMLS CUI [2,1])
C0817096 (UMLS CUI [2,2])
C3824793 (UMLS CUI [3,1])
C0000726 (UMLS CUI [3,2])
C3824793 (UMLS CUI [4,1])
C0030797 (UMLS CUI [4,2])
C3863086 (UMLS CUI [5])
C0027651 (UMLS CUI [6,1])
C0005558 (UMLS CUI [6,2])
C0034602 (UMLS CUI [7])
Disease Progression | Therapeutic procedure Discontinuation | Androgen Antagonists | abiraterone | enzalutamide | ARN-509 | Combined Modality Therapy
Item
evidence of disease progression by pcwg2 criteria during or within 4 weeks following treatment discontinuation with potent androgen signaling inhibitor, including abiraterone, enzalutamide, arn-509, or a combination.
boolean
C0242656 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C0002842 (UMLS CUI [3])
C0754011 (UMLS CUI [4])
C3496793 (UMLS CUI [5])
C2985183 (UMLS CUI [6])
C0009429 (UMLS CUI [7])
Androgen Antagonists | Androgen Antagonists Discontinuation
Item
patients must be either receiving or within 4 weeks of discontinuation of androgen signaling inhibitor at the time of pet imaging and tumor biopsy.
boolean
C0002842 (UMLS CUI [1])
C0002842 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
Age
Item
age 18 years or older at the time of study entry
boolean
C0001779 (UMLS CUI [1])
Platelet Count measurement | Prothrombin time assay | International Normalized Ratio | Activated Partial Thromboplastin Time measurement
Item
platelets >75,000/μl and pt or inr and a ptt < 1.5 times the institutional uln within 14 days prior to biopsy.
boolean
C0032181 (UMLS CUI [1])
C0033707 (UMLS CUI [2])
C0525032 (UMLS CUI [3])
C0030605 (UMLS CUI [4])
Systemic therapy
Item
intervening systemic therapy between discontinuation of androgen signaling inhibitor and planned date of gallium citrate pet.
boolean
C1515119 (UMLS CUI [1])
Therapeutic radiology procedure Targeting Metastatic Lesion | Metastatic Lesion Tumor Biopsy
Item
history of radiation therapy to the target metastatic lesion selected for tumor biopsy
boolean
C1522449 (UMLS CUI [1,1])
C1521840 (UMLS CUI [1,2])
C1513183 (UMLS CUI [1,3])
C1513183 (UMLS CUI [2,1])
C0027651 (UMLS CUI [2,2])
C0005558 (UMLS CUI [2,3])
Medical contraindication Biopsy | Bleeding tendency Uncontrolled
Item
contra-indication to biopsy including uncontrolled bleeding diathesis.
boolean
C1301624 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C1458140 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
Communicable Disease
Item
active infection within 14 days of study enrollment
boolean
C0009450 (UMLS CUI [1])
Medical contraindication MRI | PET and MRI | Artificial cardiac pacemaker | Aneurysm clip | Implants | Claustrophobia Severe
Item
contraindications for mri (for patients undergoing pet/mr study), including presence of pacemaker, aneurysm clip, implanted device, or severe claustrophobia
boolean
C1301624 (UMLS CUI [1,1])
C0024485 (UMLS CUI [1,2])
C3641326 (UMLS CUI [2])
C0030163 (UMLS CUI [3])
C0179977 (UMLS CUI [4])
C0021102 (UMLS CUI [5])
C0008909 (UMLS CUI [6,1])
C0205082 (UMLS CUI [6,2])